Abstract
Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, b-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 665-671 |
| Number of pages | 7 |
| Journal | Gut and Liver |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2016 |
Keywords
- Adenocarcinoma
- Aspirin
- Betablockers
- Bisphosphonates
- Dipeptidyl-peptidase 4 inhibitors
- Epidemiology
- Malignancy
- Metformin
- Pancreas
- Statins